EP2 Receptor Antagonist Compounds for Targeted Neuroinflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions driven by COX-2 induction, such as neuroinflammation and neurodegeneration, are inadequate due to the complexity of COX-2 signaling pathways, and there is a need for targeted modulation of specific prostaglandin receptors like EP2 to address inflammation and pain effectively.
Innovation Solution
Development of compounds that selectively antagonize the EP2 receptor, formulated into pharmaceutical compositions for various administration routes, to treat or prevent conditions related to EP2 receptor activation, including neurological disorders, inflammation, and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nonselective COX inhibition is used to treat inflammation and pain, then therapeutic effects are achieved, but harmful side effects increase due to blocking entire COX-2 cascade
Solution Approach 1:
The patent segments the COX-2 signaling pathway by selectively targeting the EP2 prostaglandin receptor rather than inhibiting the entire COX-2 cascade. This segmentation allows for precise modulation of specific proinflammatory pathways while preserving other physiological functions, thereby maintaining therapeutic efficacy while reducing harmful side effects associated with nonselective COX inhibition
Solution Approach 2:
The invention applies local quality by designing compounds with specific molecular structures (Formula I and Formula II) that selectively bind to the EP2 receptor. This selective binding enables localized modulation of PGE2/EP2 signaling in inflammatory tissues without affecting other COX pathways, achieving targeted anti-inflammatory effects with minimized systemic side effects
2Quantity of substance
If PGE2/EP2 signaling is activated to mediate inflammation response, then inflammatory mediator production increases, but neurotoxicity and tissue injury are exacerbated
Solution Approach 1:
The patent converts the harmful effect of PGE2/EP2 signaling into a beneficial therapeutic target. By designing EP2 receptor antagonists that block this pathway, the invention transforms the understanding of PGE2/EP2-mediated neurotoxicity into a treatment strategy for status epilepticus and neuroinflammatory diseases, where inhibiting this pathway protects neurons from damage
Solution Approach 2:
The invention applies preliminary anti-action by administering EP2 receptor antagonists before or during the onset of status epilepticus to prevent neurotoxicity. The compounds preemptively block PGE2/EP2 signaling pathways that would otherwise be activated during seizures, thereby preventing neuronal damage before it occurs
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate selective inhibition of the EP2 receptor, reducing inflammation and neurotoxicity, and show potential in treating a wide range of diseases and conditions by inhibiting PGE2/EP2 signaling pathways.
Implementation Method 1
certain compounds antagonize EP2 signaling... the compounds display selectivity in inhibiting the EP2 receptor over the EP4 receptor
Data Source
AI summary
The disclosure relates to Prostaglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, epilepsy, neuroinflamation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof.